KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Gains from Investment Securities (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Gains from Investment Securities for 15 consecutive years, with $51000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities fell 17.74% year-over-year to $51000.0, compared with a TTM value of $51000.0 through Sep 2025, down 17.74%, and an annual FY2024 reading of $57000.0, down 20.83% over the prior year.
  • Gains from Investment Securities was $51000.0 for Q3 2025 at TherapeuticsMD, roughly flat from $51000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $23.5 million in Q2 2021 and bottomed at -$721000.0 in Q3 2023.
  • Average Gains from Investment Securities over 5 years is $1.6 million, with a median of $59500.0 recorded in 2024.
  • The sharpest move saw Gains from Investment Securities tumbled 72200.0% in 2023, then skyrocketed 75262.32% in 2025.
  • Year by year, Gains from Investment Securities stood at $353000.0 in 2021, then plummeted by 51.27% to $172000.0 in 2022, then crashed by 58.14% to $72000.0 in 2023, then dropped by 20.83% to $57000.0 in 2024, then decreased by 10.53% to $51000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for TXMD at $51000.0 in Q3 2025, $51000.0 in Q2 2025, and $52000.0 in Q1 2025.